Slide 1Adis R&D Insight Vendor Update SLA P&HT Division Meeting April 8, 2008 Slide 2 Total number of RDI drug profiles = 23,296Total number of RDI drug profiles…

PowerPoint Presentation DNA-Based Non-Surgical Angiogenic Therapy 11-Jan-13 Product & Technology Overview Generx® Angiogenic Therapy Regenerative Medicine for Interventional…

Slide 1 ADCs: the opportunity Barry Heavey, Head of Life Sciences IDA Ireland June 20 th, 2014 Slide 2 ADC market opportunity –Herceptin:  Launched 1998  patent expiration…

Slide 1 BIO Europe, November 2013 Antimicrobial peptides with novel mode of action Slide 2 A NTIMICROBIAL PEPTIDES WITH NOVEL MODE OF ACTION Adenium Biotech - Background…

Slide 1 Corporate presentation, BIO, Chicago 2013 Developing novel antimicrobials against ”difficult to treat” multi drug resistant bacteria Confidential Summary –…

* - USA Adis R&D Insight SLA â Pipeline Town Hall Ben Weintraub and Jeff Southwood WHY ADIS R&D INSIGHT * - USA * Why? â Experience, Expertise, and Timeliness Editorial…

Corporate presentation December 2013 Antimicrobial peptides with novel mode of action 1 Antimicrobial peptides with novel mode of action Adenium Biotech - Background Spin-out…

BIO Europe, November 2013 Antimicrobial peptides with novel mode of action 1 Antimicrobial peptides with novel mode of action Adenium Biotech - Background Spin-out from Novozymes,…

Portfolio of Qualifying Experience Workshop Networking Education Technology Eddie D. Blanton, CCIM CCIM Designee, May 3, 2001 NC CCIM Chapter Board Member Since 2003 Resume…

PowerPoint Presentation ADCs: the opportunity Barry Heavey, Head of Life Sciences IDA Ireland June 20th, 2014 ADC market opportunity Herceptin: Launched 1998 patent expiration…